# UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.

> **NCT05148377** · PHASE3 · COMPLETED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 128 (actual)

## Conditions studied

- Hemodialysis Complication

## Interventions

- **DRUG:** Liquaemin
- **DRUG:** Heptar

## Key facts

- **NCT ID:** NCT05148377
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-01
- **Primary completion:** 2008-12-01
- **Final completion:** 2008-12-01
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2021-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05148377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05148377, "UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05148377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*